Payment overview · 2025
General Payments
$289.82
14 reported records · 6 companies
Healthcare provider profile · identity verified
Stephen Montgomery, MD
Allopathic & Osteopathic Physicians|Family Medicine · PONTOTOC, MS · NPI 1699735159
Verified facts
What the public records show
CMS Open Payments records show Stephen Montgomery, MD received $289.82 in general payments during 2025 across 14 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $89.42 | 30.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.72 | 19.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $52.18 | 18.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.19 | 12.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.99 | 10.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.32 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $289.82 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $141.60 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.72 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.72 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 368 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
368 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 796 | 187 |
| Pantoprazole Sodium | Pantoprazole Sodium | 739 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 715 | 160 |
| Gabapentin | Gabapentin | 693 | 119 |
| Carvedilol | Carvedilol | 620 | 135 |
| Losartan Potassium | Losartan Potassium | 603 | 141 |
| Hydrochlorothiazide | Hydrochlorothiazide | 530 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 504 | 93 |
| Potassium Chloride | Potassium Chloride | 412 | 98 |
| Furosemide | Furosemide | 405 | 105 |
| Omeprazole | Omeprazole | 404 | 98 |
| Famotidine | Famotidine | 373 | 81 |
| Eliquis | Apixaban | 368 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 367 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 323 | 81 |
| Ezetimibe | Ezetimibe | 297 | 57 |
| Lisinopril | Lisinopril | 289 | 71 |
| Metformin Hcl Er | Metformin Hcl | 281 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 275 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 229 | 40 |
| Simvastatin | Simvastatin | 221 | 56 |
| Allopurinol | Allopurinol | 220 | 42 |
| Montelukast Sodium | Montelukast Sodium | 212 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 37 |
| Tramadol Hcl | Tramadol Hcl | 196 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 46 |
| Buspirone Hcl | Buspirone Hcl | 190 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 188 | 44 |
| Sertraline Hcl | Sertraline Hcl | 186 | 47 |
| Metformin Hcl | Metformin Hcl | 171 | 47 |
| Trazodone Hcl | Trazodone Hcl | 171 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 34 |
| Farxiga | Dapagliflozin Propanediol | 147 | 20 |
| Spironolactone | Spironolactone | 146 | 31 |
| Jardiance | Empagliflozin | 142 | 19 |
| Memantine Hcl | Memantine Hcl | 139 | 24 |
| Mirtazapine | Mirtazapine | 138 | 31 |
| Glimepiride | Glimepiride | 124 | 32 |
| Warfarin Sodium | Warfarin Sodium | 124 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 30 |
| Donepezil Hcl | Donepezil Hcl | 122 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 27 |
| Alprazolam | Alprazolam | 119 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 97 | 20 |
| Meclizine Hcl | Meclizine Hcl | 95 | 26 |
| Synthroid | Levothyroxine Sodium | 93 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 15 |
| Pregabalin | Pregabalin | 84 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 83 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 60 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 17 |
| Azithromycin | Azithromycin | 72 | 58 |
| Fluconazole | Fluconazole | 72 | 37 |
| Linzess | Linaclotide | 71 | 13 |
| Xarelto | Rivaroxaban | 67 | suppressed |
| Chlorthalidone | Chlorthalidone | 66 | 11 |
| Valsartan | Valsartan | 66 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 18 |
| Cephalexin | Cephalexin | 63 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 17 |
| Levetiracetam | Levetiracetam | 61 | suppressed |
| Clonazepam | Clonazepam | 59 | 13 |
| Nystatin | Nystatin | 59 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 35 |
| Ondansetron Odt | Ondansetron | 55 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 54 | suppressed |
| Atenolol | Atenolol | 52 | 11 |
| Mometasone Furoate | Mometasone Furoate | 52 | 34 |
| Propafenone Hcl | Propafenone Hcl | 52 | suppressed |
| Sucralfate | Sucralfate | 52 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | suppressed |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Meloxicam | Meloxicam | 47 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 46 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 45 | 11 |
| Clonidine Hcl | Clonidine Hcl | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 41 | 21 |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Colchicine | Colchicine | 36 | 15 |
| Cilostazol | Cilostazol | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 34 | suppressed |
| Digoxin | Digoxin | 33 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | 11 |
| Levofloxacin | Levofloxacin | 32 | 28 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 24 |
| Risperidone | Risperidone | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 20 |
| Ozempic | Semaglutide | 27 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Tivicay | Dolutegravir Sodium | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Prednisone | Prednisone | 23 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 14 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Nitroglycerin | Nitroglycerin | 20 | 13 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 18 |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 12 |
| Latanoprost | Latanoprost | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 12 |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $289.82 · 14 records | Otsuka America Pharmaceutical, Inc. | ELIQUIS, EVENITY, KISUNLA, NURTEC ODT, Ozempic, PROLIA, REXULTI, Rybelsus | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error